Pay in 4 interest-free payments of $5.00 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Patients should continue evidence-based lipid-lowering therapy as recommended by NICE guidelines whilst considering GLP-1 therapy for its licensed indications
Ultimately, by early November 2025 Metsera accepted Pfizers sweetened offer: $86.25 per share ($10.0 billion total) comprising $65.60 cash and up to $20.65 in contingent value rights (CVRs) ( [6] ) ( [7] )
Increasing the dose yourself can be harmful to your health and increase the chances of experiencing side effects with retatrutide
Severe stomach problems
This is known as step therapy
US$ 24.91
US$ 20.12
US$ 20.91
US$ 28.85
US$ 27.95
US$ 24.95
